

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Tagrisso Prior Authorization Policy

- Tagrisso® (osimertinib tablets – AstraZeneca)

REVIEW DATE: 01/31/2024; selected revision 10/16/2024

OVERVIEW

Tagrisso, a tyrosine kinase inhibitor, is indicated for the following uses:¹

- **Non-Small Cell Lung Cancer (NSCLC) – Epidermal growth factor receptor (*EGFR*) Mutation-Positive:**
 - First-line treatment of **metastatic NSCLC** tumors that have *EGFR* exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test, in adults.
 - Tagrisso, **in combination with Alimta** (pemetrexed for intravenous use) **and platinum-based chemotherapy** is indicated for the first-line treatment of locally advanced or metastatic NSCLC that have *EGFR* exon 19 or exon 21 L858R mutations, as detected by an FDA-approved test, in adults.
- **NSCLC – *EGFR* T790M Mutation-Positive:** Treatment of metastatic *EGFR* T790M mutation-positive NSCLC, as detected by an FDA-approved test, in adults whose disease has progressed on or after *EGFR* tyrosine kinase inhibitor (TKI) therapy.
- **NSCLC – *EGFR* Mutation-Positive, Post Tumor Resection:** Adjuvant therapy after tumor resection in adults with NSCLC whose tumors have *EGFR* exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- **NSCLC – *EGFR* Mutation-Positive, Unresectable (Stage III) Disease:** Treatment of locally advanced, unresectable (stage III) NSCLC in adults whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have *EGFR* exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Guidelines

National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (version 10.2024 – September 23, 2024) recommend testing for *EGFR* mutations in patients with metastatic disease.² The most common *EGFR* mutations are exon 19 deletion and exon 21 (L858R) substitution mutations. Other less common mutations that are also responsive to *EGFR* tyrosine kinase inhibitors (TKIs) include L861Q, G719X, and S768I. NCCN recommends Tagrisso as the “Preferred” first-line treatment for patients with *EGFR* exon 19 deletion or exon 21 (L858R) substitution mutations. Tagrisso can also be used in combination with Alimta® (pemetrexed for injection) and either cisplatin or carboplatin in the first-line setting (category 1, “Other Recommended” regimens). Tagrisso is also a recommended “Preferred” first-line therapy (category 2A) for *EGFR* mutations L861Q, G719X, and S768I. Tagrisso is also recommended as subsequent treatment for all of these mutations. The panel recommends T790M (a secondary mutation in *EGFR*) testing in patients who progress on erlotinib tablets, Gilotrif® (afatinib tablets), Iressa® (gefitinib tablets), or Vizimpro® (dacomitinib tablets). If the patient has *EGFR* T790M-positive metastatic NSCLC, Tagrisso is recommended as subsequent therapy (category 1). If the disease is *EGFR* T790M-negative, the patient can be continued on the current TKI (i.e., erlotinib, Gilotrif, Iressa, or Vizimpro). Tagrisso is also recommended for use in patients with completely resected stage IB-IIIa *EGFR* (exon 19 deletion, L858R) NSCLC who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy. Tagrisso is recommended for stage IIIa unresectable disease (category 1) after definitive chemoradiation for *EGFR* exon 19 deletion or L858R mutation. A footnote also states that for patients who have received sequential chemoradiation, Imfinzi (durvalumab intravenous infusion) can be considered, or if *EGFR* exon 19 deletion or L858R, Tagrisso is recommended.

01/31/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Tagrisso. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tagrisso is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Non-Small Cell Lung Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B and C):

A) Patient is ≥ 18 years of age; AND

B) Patient has advanced or metastatic disease; AND

C) Patient meets ONE of the following (i or ii):

- i. Patient has epidermal growth factor receptor (*EGFR*) mutation-positive disease as detected by an approved test; OR

Note: Examples of *EGFR* mutation-positive non-small cell lung cancer include the following: exon 19 deletion, exon 21 (L858R) substitution mutations, L861Q, G719X, and S768I.

- ii. Patient meets BOTH of the following (a and b):

a) Patient has epidermal growth factor receptor (*EGFR*) T790M mutation-positive disease as detected by an approved test; AND

b) Patient has progressed on treatment with at least one of the *EGFR* tyrosine kinase inhibitors.

Note: *EGFR* tyrosine kinase inhibitors are erlotinib, Iressa (gefitinib tablets), Vizimpro (dacomitinib tablets), Gilotrif (afatinib tablets).

2. **Non-Small Cell Lung Cancer – Post Tumor Resection.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

A) Patient is ≥ 18 years of age; AND

B) Patient has completely resected disease; AND

C) Patient has *EGFR* exon 19 deletion or exon 21 (L858R) substitution mutation as detected by an approved test; AND

D) Patient meets ONE of the following (i or ii):

- i. Patient received previous adjuvant chemotherapy; OR

- ii. Patient is ineligible to receive platinum-based chemotherapy.

3. **Non-Small Cell Lung Cancer – Unresectable, Stage III.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

A) Patient is ≥ 18 years of age; AND

B) Patient has locally advanced, unresectable (stage III) disease; AND

C) Patient has *EGFR* exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an approved test; AND

D) Patient has not had disease progression during or following platinum-based chemoradiation therapy.

Note: Patient could have received concurrent or sequential chemoradiation therapy.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Tagrisso is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tagrisso™ tablets [prescribing information]. Wilmington, DE: AstraZeneca; September 2024
2. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 10.2024 – September 23, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 14, 2024.